Se connecter S'abonner en ligne
  • Infos sociétés
  • Infos OPCVM
  • Alertes e-mail
  • Notre offre
 Langues  Par thème  Par secteur d'activité  Par pays
Cantabio Pharmaceuticals Inc. [US13808X2036]   
[06/02/2024]

Cantabio Pharmaceuticals Inc. : Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease

Grant enables the further development of Cantabios innovative DJ1 replacement therapy, which have high therapeutic potential in both diseasemodifying and preventive contexts for the treatment of Parkinsons disease.SAN MATEO, CA / ACCESSWIRE / February 6, 2024 / Cantabio Pharmaceuticals, Inc. "Cantabio" or the "Company", a preclinical stage pharmaceutical company developing... Lire le communiqué
 
Cantabio Pharmaceuticals Inc. [US13808X2036]   
[05/01/2022]

Cantabio Pharmaceuticals Inc. : Cantabio Pharmaceuticals Awarded Grant From The Michael J. Fox Foundation to Develop Novel Small-Molecule Aggregation Inhibitors of the Tau Protein for the Treatment of Parkinson’s Disease

Grant enables the further development of Cantabios novel smallmolecule tau protein aggregation inhibitors, which have high therapeutic potential in both diseasemodifying and preventive contexts for the treatment of Parkinsons and Alzheimers disease.PALO ALTO, CA / ACCESSWIRE / January 5, 2022 / Cantabio Pharmaceuticals, Inc. "Cantabio" or the "Company", a preclinical stage... Lire le communiqué
 


Vidéos
Gestionnaires,
Emetteurs,
Ma sélection
Les communiqués les plus lus de Cantabi...